Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer
September 22, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 15, 2021 16:01 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia
August 18, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131
August 16, 2021 08:30 ET
|
Cellectar Biosciences
Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 131) Agreement adds second manufacturer and expands Cellectar’s current supply capabilities FLORHAM PARK,...
Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update
August 09, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.
July 13, 2021 09:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)
July 12, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
July 08, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors
June 24, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., June 24, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2021 09:00 ET
|
Cellectar Biosciences
Mean treatment free remission 1.1 years and remains ongoing Progression free survival for MYD88 wild type and high-risk patients 18 months and ongoing FLORHAM PARK, N.J., June 04, 2021 (GLOBE...